Hjem › Akut myelogen leukemi › Oklahoma
Kliniske studier for Akut myelogen leukemi i Oklahoma
14 studier for Akut myelogen leukemi søker deltakere på steder i Oklahoma.
Byer i Oklahoma
Offisiell studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545Pilot Imaging Study of Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1
Alder 4 til 80 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT03633955A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. mai 2024 · NCT04905810Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.